$RVP
RETRACTABLE TECHNOLOGIES INC Stock $rvp

$rvp Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000110465913084655 Filed on November 14, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$7.540M	$9.160M	$9.444M
YoY Change	-6.22%	-3.01%	14.19%
Cost Of Revenue	$5.070M	$5.842M	$6.090M
YoY Change	-20.66%	-4.07%	24.78%
Gross Profit	$2.480M	$3.318M	$3.354M
YoY Change	50.3%	-1.07%	-1.06%
Gross Profit Margin	32.89%	36.22%	35.51%
Selling, General & Admin	$3.640M	$3.875M	$3.321M
YoY Change	-7.38%	16.68%	2.29%
% of Gross Profit	146.77%	116.8%	99.03%
Research & Development	$190.0K	$268.0K	$244.0K
YoY Change	-29.63%	9.83%	44.15%
% of Gross Profit	7.66%	8.08%	7.28%
Depreciation & Amortization	$320.0K	$330.0K	$320.0K
YoY Change	-8.57%	3.13%	-5.88%
% of Gross Profit	12.9%	9.95%	9.54%
Operating Expenses	$3.830M	$4.143M	$3.565M
YoY Change	-8.81%	16.21%	4.37%
Operating Profit	-$1.350M	-$825.3K	-$211.4K
YoY Change	-47.06%	290.43%	701.46%
Interest Expense	-$50.00K	$59.53K	$68.99K
YoY Change	400.0%	-13.71%	10.47%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.400M	-$878.3K	-$269.1K
YoY Change	-45.31%	226.39%	-114.73%
Income Tax	$30.00K	$62.09K	$3.869K
% Of Pretax Income
Net Earnings	-$1.650M	-$940.4K	-$273.0K
YoY Change	-40.43%	244.51%	-114.93%
Net Earnings / Revenue	-21.88%	-10.27%	-2.89%
Basic Earnings Per Share		-$0.04	-$0.02
Diluted Earnings Per Share	-$0.06	-$0.04	-$0.02
COMMON SHARES
Basic Shares Outstanding	26.97M shares		26.97M shares
Diluted Shares Outstanding			26.97M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.63M	$27.27M	$25.01M
YoY Change	6.43%	9.04%	-7.1%
Cash & Equivalents	$27.63M	$27.27M	$25.01M
Short-Term Investments
Other Short-Term Assets	$1.066M	$323.5K	$672.9K
YoY Change	35.97%	-51.93%	460.78%
Inventory	$5.736M	$6.112M	$4.946M
Prepaid Expenses
Receivables	$3.477M	$4.812M	$5.221M
Other Receivables	$0.00	$10.00K	$80.00K
Total Short-Term Assets	$37.91M	$38.53M	$35.93M
YoY Change	6.96%	7.24%	-11.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.91M	$11.16M	$11.98M
YoY Change	-8.32%	-6.88%	-4.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00
YoY Change
Total Long-Term Assets	$11.19M	$11.44M	$12.31M
YoY Change	-8.21%	-7.1%	-5.01%
TOTAL ASSETS
Total Short-Term Assets	$37.91M	$38.53M	$35.93M
Total Long-Term Assets	$11.19M	$11.44M	$12.31M
Total Assets	$49.10M	$49.97M	$48.24M
YoY Change	3.08%	3.58%	-9.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.108M	$5.201M	$2.738M
YoY Change	0.15%	89.95%	-6.54%
Accrued Expenses	$1.670M	$1.920M	$1.910M
YoY Change	39.17%	0.52%	4.37%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$247.1K	$279.1K	$310.6K
YoY Change	-21.59%	-10.13%	-52.95%
Total Short-Term Liabilities	$16.62M	$16.40M	$5.962M
YoY Change	105.78%	175.11%	-7.29%
LONG-TERM LIABILITIES
Long-Term Debt	$3.577M	$3.626M	$3.914M
YoY Change	-6.52%	-7.35%	-3.84%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$3.577M	$3.626M	$3.914M
YoY Change	-6.52%	-7.35%	-3.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.62M	$16.40M	$5.962M
Total Long-Term Liabilities	$3.577M	$3.626M	$3.914M
Total Liabilities	$20.20M	$20.03M	$9.875M
YoY Change	69.68%	102.8%	-5.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.98M	-$28.56M	-$21.23M
YoY Change	26.14%	34.53%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock	$58.98M	$58.60M	$58.67M
YoY Change	0.62%	-0.13%
Treasury Stock (at cost)	$1.097M	$1.097M	$83.79K
YoY Change	797.37%	1208.73%
Treasury Stock Shares	722.9K shares
Shareholders Equity	$28.90M	$29.94M	$38.37M
YoY Change
Total Liabilities & Shareholders Equity	$49.10M	$49.97M	$48.24M
YoY Change	3.08%	3.58%	-9.79%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$1.650M	-$940.4K	-$273.0K
YoY Change	-40.43%	244.51%	-114.93%
Depreciation, Depletion And Amortization	$320.0K	$330.0K	$320.0K
YoY Change	-8.57%	3.13%	-5.88%
Cash From Operating Activities	$70.00K	$8.260M	$1.050M
YoY Change	-94.85%	686.67%	38.16%
INVESTING ACTIVITIES
Capital Expenditures	-$80.00K	-$40.00K	-$120.0K
YoY Change	-65.22%	-66.67%	-36.84%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$80.00K	-$40.00K	-$120.0K
YoY Change	-65.22%	-66.67%	-36.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	360.0K	-630.0K	1.180M
YoY Change	-300.0%	-153.39%	-368.18%
NET CHANGE
Cash From Operating Activities	70.00K	8.260M	1.050M
Cash From Investing Activities	-80.00K	-40.00K	-120.0K
Cash From Financing Activities	360.0K	-630.0K	1.180M
Net Change In Cash	350.0K	7.590M	2.110M
YoY Change	-63.16%	259.72%	1523.08%
FREE CASH FLOW
Cash From Operating Activities	$70.00K	$8.260M	$1.050M
Capital Expenditures	-$80.00K	-$40.00K	-$120.0K
Free Cash Flow	$150.0K	$8.300M	$1.170M
YoY Change	-90.57%	609.4%	23.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	204514	USD
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-236255	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	37325	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	974407	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	172839	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	34199	USD
	us-gaap	Interest Expense InterestExpense	211344	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	59533	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62085	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	13534753	USD
	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	1872553	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3235528	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	648224	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8527295	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	27149	USD
	us-gaap	Interest Expense InterestExpense	172236	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65836	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	957090	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1122194	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1167368	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-460253	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	101609	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	527466	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	63328	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11899650	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	809592	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1
	dei	Entity Registrant Name EntityRegistrantName	RETRACTABLE TECHNOLOGIES INC
	dei	Entity Central Index Key EntityCentralIndexKey	0000946563
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26972837	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25963313	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3694307	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	4990253	USD
CY2012Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	9431	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	783760	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	35441064	USD
CY2012Q4	rvp	Intangible Assets And Other Assets Noncurrent IntangibleAssetsAndOtherAssetsNoncurrent	291444	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5099884	USD
CY2012Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	57613	USD
CY2012Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	129107	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1665670	USD
CY2012Q4	us-gaap	Additional Paid In Capital Preferred Stock AdditionalPaidInCapitalPreferredStock	58617308	USD
CY2012Q4	us-gaap	Liabilities Liabilities	11903162	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	315086	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8076952	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3826210	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23767662	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	122202	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	35728996	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47632158	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49967333	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	29940811	USD
CY2013Q3	us-gaap	Liabilities Liabilities	20026522	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue		USD
CY2013Q3	us-gaap	Assets Assets	49967333	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	38528815	USD
CY2013Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	63328	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1
CY2012Q3	us-gaap	Sales Revenue Net SalesRevenueNet	9444157	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	25602046	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	14114956	USD
	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	1962780	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16077736	USD
	us-gaap	Gross Profit GrossProfit	9524310	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2939142	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	601008	USD
	us-gaap	Operating Expenses OperatingExpenses	10912813	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1388503	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1565648	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	26372	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2280601	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2012Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5318351	USD
CY2012Q3	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	772142	USD
CY2012Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6090493	USD
CY2012Q3	us-gaap	Gross Profit GrossProfit	3353664	USD
CY2012Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1034419	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	244015	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2286614	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	3565048	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-211384	USD
CY2012Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	11286	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	68994	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-269092	USD
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3869	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-272961	USD
CY2012Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	229527	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-502488	USD
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2013Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5842476	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	3317802	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15407306	USD
	us-gaap	Gross Profit GrossProfit	7833317	USD
	us-gaap	Operating Expenses OperatingExpenses	12411047	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	4143119	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-825317	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4577730	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4722817	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-878299	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-940384	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4788653	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5475719	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1169383	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	986761	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	52775	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	30854	USD
	us-gaap	Inventory Write Down InventoryWriteDown	90000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000	USD
	us-gaap	Accretion Expense AccretionExpense	3773	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1201385	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1675218	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	39849	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	454412	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-761912	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1009720	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1174	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-203514	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	83792	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	172838	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	820077	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-664575	USD
	us-gaap	Interest Paid InterestPaid	207571	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	71328	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	57613	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	2858132	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1346176	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	1308442	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1620000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25008688	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25673263	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27271755	USD
	rvp	Number Of Products Consigned To Customers NumberOfProductsConsignedToCustomers	0	item
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P17Y
CY2013Q3	rvp	Number Of Significant Customers NumberOfSignificantCustomers	3	item
	rvp	Number Of Significant Customers NumberOfSignificantCustomers	2	item
	rvp	Number Of Significant Customers NumberOfSignificantCustomers	3	item
CY2012Q4	rvp	Allowance For Contractual Pricing AllowanceForContractualPricing	3000000	USD
CY2013Q3	rvp	Allowance For Contractual Pricing AllowanceForContractualPricing	4400000	USD
	rvp	Increase Decrease In Reserve For Non Contractual Rebates IncreaseDecreaseInReserveForNonContractualRebates	0	USD
	rvp	Revenue Recognition Period For Return Of Incorrect Shipments RevenueRecognitionPeriodForReturnOfIncorrectShipments	P10D
	rvp	Revenue Recognition Overstock Return Limit Number RevenueRecognitionOverstockReturnLimitNumber	2	item
	rvp	Revenue Recognition Overstock Return Period RevenueRecognitionOverstockReturnPeriod	P12M
	rvp	Revenue Recognition Maximum Percentage Of Distributors Total Purchase In Prior Twelve Month Period For Overstock Return RevenueRecognitionMaximumPercentageOfDistributorsTotalPurchaseInPriorTwelveMonthPeriodForOverstockReturn	0.01	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1076523	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	759620	shares
CY2013Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	228999	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	687066	USD
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4811675	USD
CY2013Q3	us-gaap	Inventory Net InventoryNet	6112447	USD
CY2012Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1692133	USD
CY2013Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1681029	USD
CY2012Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3537872	USD
CY2013Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4671170	USD
CY2012Q4	us-gaap	Inventory Gross InventoryGross	5230005	USD
CY2013Q3	us-gaap	Inventory Gross InventoryGross	6352199	USD
CY2012Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	239752	USD
CY2013Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	239752	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.014	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.017	pure
CY2013Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.071	pure
CY2012Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.014	pure
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1778570	USD
CY2012Q4	us-gaap	Customer Advances Current CustomerAdvancesCurrent	1400740	USD
CY2013Q3	us-gaap	Customer Advances Current CustomerAdvancesCurrent	1216157	USD
CY2013Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	307342	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	162969	USD
CY2013Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	122685	USD
CY2012Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	101961	USD
CY2013Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	132386	USD
CY2012Q4	us-gaap	Entity Wide Disclosure On Geographic Areas Long Lived Assets In Entitys Country Of Domicile EntityWideDisclosureOnGeographicAreasLongLivedAssetsInEntitysCountryOfDomicile	11679592	USD
CY2013Q3	us-gaap	Entity Wide Disclosure On Geographic Areas Long Lived Assets In Entitys Country Of Domicile EntityWideDisclosureOnGeographicAreasLongLivedAssetsInEntitysCountryOfDomicile	10916085	USD
CY2012Q4	us-gaap	Entity Wide Disclosure On Geographic Areas Long Lived Assets In Foreign Countries EntityWideDisclosureOnGeographicAreasLongLivedAssetsInForeignCountries	220058	USD
CY2013Q3	us-gaap	Entity Wide Disclosure On Geographic Areas Long Lived Assets In Foreign Countries EntityWideDisclosureOnGeographicAreasLongLivedAssetsInForeignCountries	240150	USD
CY2013Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	316909	shares
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	655818	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt 24.5pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Accounting estimates</font></b></p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 24.5pt;"> </p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 24.5pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from those estimates.</font></p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 24.5pt;"> </p> </div>
CY2013Q3	rvp	Intangible Assets And Other Assets Noncurrent IntangibleAssetsAndOtherAssetsNoncurrent	282283	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5201493	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt 24.5pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Concentration risks</font></b></p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 24.5pt;"> </p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 24.5pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company’s financial instruments exposed to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable.  Cash balances, some of which exceed federally insured limits, are maintained in financial institutions; however, Management believes the institutions are of high credit quality.  The majority of accounts receivable are due from companies which are well-established entities.  As a consequence, Management considers any exposure from concentrations of credit risks to be limited.</font></p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 24.5pt;"> </p> <p style="MARGIN: 0in 0in 0pt 24.5pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table reflects our significant customers in 2013 and 2012:</font></p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 24.5pt;"> </p> <table style="text-align:left;WIDTH: 95.46%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 24.5pt;" border="0" cellspacing="0" cellpadding="0" width="95%"> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 29.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="29%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Nine Months ended<br /> September 30, 2013</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Nine Months ended<br /> September 30, 2012</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three Months ended<br /> September 30, 2013</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three Months ended<br /> September 30, 2012</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 29.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="29%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 9pt;" size="1">Number of significant customers</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 29.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="29%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 9pt;" size="1">Aggregate dollar amount of net sales to significant customers</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$7.6 million</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$10.6 million</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$4.3 million</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$3.4 million</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 29.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="29%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 9pt;" size="1">Percentage of net sales to significant customers</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">32.9%</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">41.3%</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">47.4%</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">35.6%</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr></table> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 24.5pt;"> </p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 24.5pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company manufactures syringes in Little Elm, Texas as well as utilizing manufacturers in China.  The Company purchases most of its product components from single suppliers, including needle adhesives and packaging materials.  There are multiple sources of these materials.  The Company obtained roughly 73.1% and 69.6% of its finished products in the first nine months of 2013 and 2012, respectively, from Double Dove, a Chinese manufacturer.  Purchases from Double Dove aggregated 75.6% and 71.9% of finished products in the three month periods ended September 30, 2013 and 2012, respectively.  In the event that the Company becomes unable to purchase such product from Double Dove, the Company would need to find an alternate supplier for its 0.5mL insulin syringe, its 2 mL, 5mL, and 10mL syringes and its autodisable syringe and increase domestic production for 1mL and 3mL syringes.</font></p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 24.5pt;"> </p> </div>
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	279083	USD
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	605221	USD
CY2013Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	748044	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	16400565	USD
CY2013Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3625957	USD
CY2013Q3	us-gaap	Additional Paid In Capital Preferred Stock AdditionalPaidInCapitalPreferredStock	58598790	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28556315	USD
CY2013Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1096609	USD
CY2013Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5094432	USD
CY2013Q3	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	748044	USD
CY2013Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1092505	USD
CY2013Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	7724826	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	9160278	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	23240623	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue		USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	9431	USD
CY2013Q3	us-gaap	Other Assets Current OtherAssetsCurrent	323507	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11156235	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	267991	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2782623	USD
CY2013Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	6551	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	50000	USD
	rvp	Increase Decrease In Litigation Reserve IncreaseDecreaseInLitigationReserve	7724826	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25870073	shares
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26972818	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27000158	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26719608	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1640480	shares
CY2012Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	666899	shares

Files In Submission

Name	View Source	Status
0001104659-13-084655-index-headers.html	Edgar Link	pending
0001104659-13-084655-index.html	Edgar Link	pending
0001104659-13-084655.txt	Edgar Link	pending
0001104659-13-084655-xbrl.zip	Edgar Link	pending
a13-19620_110q.htm	Edgar Link	pending
a13-19620_1ex31d1.htm	Edgar Link	pending
a13-19620_1ex31d2.htm	Edgar Link	pending
a13-19620_1ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvp-20130930.xml	Edgar Link	completed
rvp-20130930.xsd	Edgar Link	pending
rvp-20130930_cal.xml	Edgar Link	unprocessable
rvp-20130930_def.xml	Edgar Link	unprocessable
rvp-20130930_lab.xml	Edgar Link	unprocessable
rvp-20130930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVP
RETRACTABLE TECHNOLOGIES INC Stock $rvp

2013 Q4 Form 10-Q Financial Statement

#000110465913084655 Filed on November 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVP RETRACTABLE TECHNOLOGIES INC Stock $rvp

2013 Q4 Form 10-Q Financial Statement

#000110465913084655 Filed on November 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVP
RETRACTABLE TECHNOLOGIES INC Stock $rvp